Li Li, commissioner of China's National Medical Products Administration (NMPA), met with a delegation led by Alisher Temirov, acting director of the Center for the Safety of Pharmaceutical Products of the Ministry of Health of Uzbekistan, in Beijing on June 27.

The two sides held in-depth and pragmatic discussions on strengthening China-Uzbekistan cooperation and exchanges in drug regulation, and signed a memorandum of understanding on regulatory cooperation regarding drugs and medical devices between China's NMPA and the center.

Li noted that President Xi Jinping proposed the China-Central Asia Spirit of "mutual respect, mutual trust, mutual benefit, and mutual assistance for the joint pursuit of modernization through high-quality development" at the second China-Central Asia Summit in June.

Li emphasized that both sides should carry forward this spirit by enhancing collaboration in the regulation of drugs and medical devices, advancing the high-quality development of the pharmaceutical industries as well as economic and trade exchanges between the two countries, and jointly safeguarding and promoting public health in both countries.

Li also introduced the NMPA's efforts to comprehensively deepen the reform of drugs and medical device regulation, with a focus on ensuring a high level of safety, promoting high-quality development and strengthening effective regulation. Temirov briefed the attendees on the Center for the Safety of Pharmaceutical Products and the pharmaceutical industry in Uzbekistan.

Both sides agreed to actively implement the signed memorandum of understanding, jointly promote regulatory cooperation and safeguard public health.